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Objectives The purpose of this study was to evaluate the safety and effectiveness of the Edwards SAPIEN transcatheter
heart valve (Edwards Lifesciences LLC, Irvine, California) in the pulmonary position in patients with moderate to
severe pulmonary regurgitation with or without stenosis.
Background Transcatheter pulmonary valve replacement is evolving, but to date, experience has been limited to the Melody
valve (Medtronic Inc., Minneapolis, Minnesota).
Methods Eligible patients with dysfunctional right ventricle-to-pulmonary artery conduits were screened if body weight was
35 kg and the in situ conduit diameter was 16 mm and 24 mm. Standardized implantation and follow-up
protocols were used.
Results Thirty-six patients from 4 centers were recruited between April 2008 and May 2010. Mean body weight was
73.4  22.9 kg. Successful valve deployment was achieved in 33 of 34 attempts (97.1%). Valve migration oc-
curred in 3 patients, with 2 requiring surgical retrieval; however, 1 patient underwent successful perventricular
valve implantation. Further intraprocedure complications included pulmonary hemorrhage (n  2), ventricular
fibrillation (n  1), and stent migration (n  1). Pullback gradient across the conduit decreased from 26.8 
18.4 mm Hg to 11.7  8.0 mm Hg (p  0.001). The right ventricular/aortic pressure ratio decreased from
0.6  0.2 to 0.4  0.1 (p  0.001). Peak Doppler gradient across the right ventricular outflow tract decreased
from 41.9  27.9 mm Hg to 19.1  13.3 mm Hg (p  0.001). At 6-month follow-up, all patients were alive. The
number of patients with New York Heart Association functional class I increased from 5 at baseline to 27 at
follow-up. Pulmonary regurgitation was 2 in 97% of patients. Freedom from reintervention was 97% with
1 patient undergoing elective placement of a second valve due to conduit-induced distortion of the initial implant.
Conclusions Transcatheter pulmonary valve replacement using the Edwards SAPIEN transcatheter heart valve is safe and
effective in patients with dysfunctional right ventricle-to-pulmonary artery conduits. (J Am Coll Cardiol 2011;
58:2248–56) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.040From the *Rush University Medical Center, Chicago, Illinois; †Cedars-Sinai Medical
Center, Los Angeles, California; ‡Duke Family Medicine Center, Durham, North
Carolina; §The Heart Hospital, London, United Kingdom; Medical University of South
Carolina, Charleston, South Carolina; ¶Children’s Hospital of Philadelphia, Philadel-
phia, Pennsylvania; #Yale-New Haven Hospital, New Haven, Connecticut; and **Ed-
wards Lifesciences, Irvine, California. The trial was sponsored and funded through
Edwards Lifesciences LLC. Dr. Hijazi is a consultant to Edwards Lifesciences. Dr. Kar
has received research grants from Abbott Vascular; and has received honoraria from and
is a consultant for Medtronic. Dr. Mullen is a proctor for Edwards Lifesciences. Dr.
Makkar has received consultancy fees, grant support, and lecture fees from Abbott,Medtronic, and Lilly; and grant support from Johnson & Johnson and St. Jude
Medical. Dr. Shirali is a consultant to, recipient of research grants from, and a
member of the advisory board of Philips Medical Systems; and has received research
grants from Edwards Lifesciences. Dr. Fogel has received grants from Edwards
Lifesciences for the COMPASSION study; has received grants from Siemens; and
payment as medical monitor for Kereos. Christopher Cain was an employee of
Edwards Lifesciences during the trial. All other authors have reported that they have
no relationships relevant to the contents of this paper to disclose.Manuscript received May 3, 2011; revised manuscript received July 18, 2011,










































2249JACC Vol. 58, No. 21, 2011 Kenny et al.
November 15, 2011:2248–56 Transcatheter Pulmonary Valve ReplacementTranscatheter pulmonary valve replacement (tPVR) pro-
vides a less invasive alternative to surgery in patients with
right ventricular-to-pulmonary artery (RV-PA) conduit
dysfunction. Since the original report using a bovine jugular
vein within a balloon-expandable stent was described in an
ovine model more than 10 years ago (1), several clinical
trials using this valve (Melody valve, Medtronic Inc., Min-
neapolis, Minnesota) in both Europe and the United States
have demonstrated effective immediate restoration of valvu-
lar competence with significant reductions in conduit pres-
sure gradients (2,3). Concerns have been raised, however,
regarding the performance of this device with early stent
fracture rates leading to potential valve dysfunction in more
than 25% of cases (4). The Edwards SAPIEN transcatheter
heart valve (THV) (Edwards Lifesciences LLC, Irvine,
California) was initially introduced as a transcatheter alter-
native to surgical valve replacement in elderly patients with
severe aortic stenosis (5). Since then, favorable safety and
efficacy have been reported in a large randomized clinical
trial involving elderly inoperable patients and high-risk
surgical patients with severe aortic valve stenosis (6). Re-
ports describing implantation in the pulmonary position for
right ventricular outflow tract conduit dysfunction, mirror-
ing valve efficacy and durability in the aortic position have
followed (7); however, to date, formal studies evaluating
valve effectiveness in the pulmonary position have not been
conducted.
The COMPASSION (COngenital Multicenter trial of
Pulmonic vAlve regurgitation Studying the SAPIEN inter-
ventional) THV was designed as a prospective, nonrandom-
ized, multicenter study to assess the safety and efficacy of the
SAPIEN THV for the treatment of dysfunctional RV-PA
conduits with moderate to severe pulmonary regurgitation
with or without stenosis. In this paper, we report the results
of phase 1 U.S. Food and Drug Administration–approved
clinical trial, with particular emphasis on restoration of valve
competency and impact on conduit stenosis. The institu-
tional review board of each participating institution ap-
proved the trial.
Methods
Patients. Between April 2008 and May 2010, 36 patients
from 4 centers (3 in the United States and 1 in Europe) were
recruited (Fig. 1). Patients with a dysfunctional RV-PA
conduit, defined as 3 pulmonary regurgitation by trans-
horacic echocardiography (TTE) or pulmonary regurgitant
raction 40% by cardiac magnetic resonance imaging
MRI) with or without stenosis, were considered eligible for
nclusion in the trial provided that body weight was 35 kg
nd the in situ conduit diameter was 16 mm and 24
m. After eligibility screening, informed consent was ob-
ained from all potential subjects and/or their legal guard-
ans. Pre-procedure baseline assessment included standard
aboratory testing as well as computed tomography (CT)
ngiography and cardiac MRI. Exercise testing was alsoonducted using a standardized
rotocol. The primary endpoint
or the trial was freedom from
evice failure or procedure-
elated death and/or reoperation
t 1 year. Secondary endpoints
ncluded freedom from major ad-
erse cardiac and cerebral events
t 6 months and evidence of
unctional improvement as as-
essed by improvement in de-
ree of pulmonary regurgitation
nd stenosis on TTE, pulmonary
egurgitation on MRI, symptoms
ssessed by New York Heart As-
ociation (NYHA) classification,
nd exercise tolerance as assessed
y cardiopulmonary exercise test-
ng. Follow-up protocol included assessment at 30 days, 6
onths, 1 year, and annually thereafter up to 5 years (Fig. 2).
tandardized protocols for echocardiography, exercise test-
ng, CT, and MRI were used. Cardiopulmonary exercise
esting was performed using a ramp workload protocol.
naerobic threshold was determined by use of the modified
-slope method. All study echocardiograms, MRI, and
xercise stress tests were interpreted in centralized (Core)
acilities.
alve and delivery system. The SAPIEN Pulmonic THV
s a radiopaque, stainless steel, balloon-expandable support
tructure (frame), with an integrated, unidirectional, trileaf-





MRI  magnetic resonance
imaging
NYHA  New York Heart
Association
RV-PA  right ventricle to
pulmonary artery







Figure 1 Flow Diagram Outlining Numbers of Patients
Recruited and Subsequent Valve Implantation Outcome
CSH  Cedar Sinai Hospital; DUMC  Duke University Medical Center;
RBH  Royal Brompton Hospital; RUMC  Rush University Medical Center;
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Transcatheter Pulmonary Valve Replacement November 15, 2011:2248–56fabric cuff. The valve tissue is fabricated from 3 equal
sections of bovine pericardium that have been preserved in
low-concentration solutions of buffered glutaraldehyde to
fully crosslink the tissue, while preserving its flexibility and
strength. The THV is treated according to the Edwards
ThermaFix process, which involves heat treatment of the
tissue in glutaraldehyde and uses ethanol and polysorbate-
80. The valve is available in 2 sizes: 23 mm (14-mm height)
and 26 mm (16-mm height). Valve delivery was achieved
using the Retroflex delivery system. These catheters consist
of a balloon catheter and a deflectable guiding catheter, and
require either 22- or 24-F hydrophilic sheaths for the 23-
and 26-mm valves, respectively. A specialized manual
crimping tool was used to symmetrically compress the valve
onto a 30-mm-long valvuloplasty balloon that was presized
to the final valve diameter. The primary operator verified
the correct valve mounting and orientation after crimping
onto the balloon.
Procedure. All procedures were performed with the pa-
tients under general endotracheal anesthesia with biplane
fluoroscopic guidance. Pretreatment with intravenous anti-
biotics was given before valve implantation. Intraprocedure
boluses of heparin were recommended to maintain activated
clotting time longer than 200 s. Hemodynamic and angio-
graphic assessment of the RV-PA conduit was performed to
determine the baseline pressure gradient and degree of
pulmonary regurgitation across the dysfunctional conduit.
The minimum diameter of the conduit was also assessed
from the angiograms in 2 orthogonal planes. Additionally,
aortic root angiography or selective coronary angiography to
assess for possible coronary compression was performed
Figure 2 Subject Schedule of Events
Follow-up data are included at baseline, discharge, 30 days, and 6 months for this
MRI  magnetic resonance imaging; NYHA  New York Heart Association; TTE before right ventricular outflow tract intervention. In all scases, pre-stenting of the conduit with a bare metal stent
was performed to provide a “landing zone” for the stented
valve. This was either performed in a separate procedure
(n  12) in anticipation of the stented valve or during the
alve implantation procedure (n  24). This 2-step proce-
ure allowed a greater margin of safety when positioning the
elatively short valve prosthesis (14 to 16 mm) and increased
he chance of the device maintaining a circular configuration
n the long term. It also reduced the risk of distal or
roximal obstruction in conduits that were generally signif-
cantly longer than the valve. The type and length of stent
sed for pre-stenting were left to the discretion of the
perator, and the stent was deployed on a BiB (balloon-in-
alloon) catheter (NuMED Inc., Hopkinton, New York) to
diameter of up to 2 mm less than the original conduit size
n stenotic conduits or slightly larger in conduits without
tenosis. Less aggressive dilation was acceptable in larger
ized original conduits if there was no persisting pressure
radient across the stent. The final measurement used to
uide the choice of SAPIEN THV was based on the
iameter of the balloon at full inflation during pre-stenting.
n conduits with stenosis, a 23-mm THV was used if the
ilated conduit diameter was 21 to 23 mm, and a 26-mm
HV was used if the dilated diameter was 23 to 26 mm. In
onduits without stenosis and with a diameter of 19 to 21
m, a 23-mm THV was used, and if the diameter was 21
o 23 mm, then a 26-mm valve was used. The SAPIEN
alve was then crimped symmetrically using a specialized
rimping device onto a 30-mm-long pre-sized balloon
atheter (volume driven instead of pressure driven). The
alve was delivered over a stiff guidewire across the pre-
. CT  computed tomography; ECG  electrocardiography;
horacic echocardiography.study
transttented area and deployed with balloon inflation. After valve
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were performed to determine whether post-deployment
high-pressure balloon dilation was necessary. At the end of
the procedure, venous hemostasis was achieved with either 2
Perclose sutures (Abbott Vascular, Abbott Park, Illinois)
placed at the beginning of the procedure or using a
figure-of-8 suture (8). Protocol recommendation included
pre-treatment with 81 mg of aspirin the evening before the
procedure and continuation of this for the duration of the
trial.
Demographic DataTable 1 Demographic Data
Age, yrs 30.3 15.1
Weight, kg 73.4 22.9
Male/female 24/12
Diagnosis
Tetralogy of Fallot 16
Ross procedure 11
Transposition of the great arteries 1
Other 8















Stent placed at time of procedure 24
Stent placed before day of procedure 12
Fluoroscopy time, min 38.2 17.1
Values are mean  SD, n, or n (range).
NYHA  New York Heart Association; RVOT  right ventricular outflow tract.
Comparative TTE, MRI, and CPET Data at BaselTable 2 Comparative TTE, MRI, and CPET D
Baselin
Transthoracic echocardiography
Conduit peak gradient, mm Hg 41.9 2
Conduit mean gradient, mm Hg 24.0 1
Estimated RV pressure, mm Hg 67.3 2
Magnetic resonance imaging*
Pulmonary regurgitant fraction, % 28.64 1
RV end-diastolic volume, ml/m2 130.9 6
Cardiopulmonary exercise testing
Peak VO2, ml/kg/min 22.1 9
RQ at peak exercise 0.9 0
Values are mean  SD. *No multiplicity adjustment was performed fo
6-month follow-up data.CPET  cardiopulmonary exercise testing; MRI  magnetic resonance
transthoracic echocardiography.Statistical analysis. All adverse events were adjudicated by
an independent clinical events committee. Summaries of
echocardiography, cardiac MRI, and exercise data were
based on the cohort of patients who had the study valve
implanted. Unless otherwise noted, the mean  SD were
calculated for each continuous variable; the number and
percentage of patients in each category were reported for
each categorical variable.
A summary of baseline demographic and clinical risk data
is presented in Table 1. Device success was defined as
deployment of the valve to the target area and removal of
the delivery catheter from the body and improvement in the
regurgitation to mild or less (2) per the earliest evaluable
echocardiogram. Time to reoperation was calculated as the
time from implantation to reoperation or last follow-up.
Freedom from reoperation was calculated using Kaplan-
Meier method (9). NYHA functional class was summarized
at baseline, 30 days, and 6 months. Select echocardio-
graphic, hemodynamic, cardiac MRI, and cardiopulmonary
exercise data were summarized at baseline and at 6 months.
A 2-sample nonpaired t test was used to analyze pulmonary
regurgitant fraction and right ventricular end-diastolic vol-
ume as measured by MRI. No multiplicity adjustment was
performed for this analysis. The Wilcoxon signed-rank test
was used to investigate the difference from baseline to 6
months for paired data. The method of Holm (10) was used
to adjust for multiplicity. Values of p  0.05 were consid-
ered statistically significant.
Results
Successful valve implantation was achieved in 33 of 34
attempts (97.1%). Eight patients underwent implantation of
a 26-mm SAPIEN valve. Comparative echocardiographic,
MRI, and exercise stress test data at baseline and 6-month
follow-up are presented in Table 2. Valve deployment was
not attempted in 2 patients due to inappropriate conduit
size in 2 and stent embolization (used for pre-stenting)
requiring surgical retrieval in another. In 3 patients, THV
nd 6-Month Follow-Upt Baseline and 6-Month Follow-Up
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retrieval was performed; however, in one, further transcath-
eter valve implantation was performed via a perventricular
approach (delivery through a catheter placed in the wall of
the right ventricular outflow tract) after the migrated valve
was removed under inflow occlusion without cardiopulmo-
nary bypass (11). In another patient, the THV was deployed
without complication in the inferior vena cava with subse-
quent successful deployment of a further valve. Device
success, therefore, using the intention-to-treat criteria men-
tioned was achieved in 31 of 36 patients (86.1%).
Intraprocedure hemodynamics are outlined in Table 3.
The mean procedure time was 144  60 min with a mean
fluoroscopy time of 38.2  17.1 min. Twenty-four patients
underwent pre-stenting of the RV-PA conduits during the
same procedure. Pullback systolic peak-to-peak gradient
across the conduit decreased from 26.8  18.4 mm Hg to
11.7  8.0 mm Hg (p  0.001). The pre-interventional
right ventricle/descending aorta pressure ratio was reduced
from 0.6 0.2% to 0.4 0.1% (p 0.001), with a significant
eduction in both the absolute systolic (from 55.3  18.2
m Hg to 42  13.2 mm Hg [p  0.001]) and diastolic
from 10.5 4.0 mm Hg to 9.2 4.3 mm Hg [p 0.036])
ight ventricular pressures. There was also a significant
ncrease in the pulmonary artery diastolic pressure (from
.3 3.1 mm Hg to 12.4 5.5 mm Hg [p 0.001]), likely
related to establishment of pulmonary valve competence.
On post-procedure angiography, pulmonary regurgitation
was graded trivial or less in 31 of 33 successful percutaneous
implants.
Seven patients (20.5%) experienced adverse events (Table 4).
Of those, 3 required surgery for migration of the THV (n 2)
and stent embolization (n  1). In all 3 cases, surgery was
uneventful with no damage to the intracardiac structures
noted as a consequence of the attempted THV implanta-
tion. In another patient, the valve migrated toward the right
ventricle after balloon inflation, and it was deployed without
complication in the inferior vena cava. Mild intraprocedure
pulmonary hemorrhage developed in 2 patients, thought to
be related to the position of the stiff guidewire in the distal
pulmonary vascular bed; neither required any specific treat-
ment. Two episodes of ventricular fibrillation occurred in 1





RV systolic pressure, mm Hg 55.3 18.2 42 13.2 0.001
RV diastolic pressure, mm Hg 10.5 4.0 9.2 4.3 0.036
Mean PA pressure, mm Hg 16.0 5.2 30 8.2 0.001
Diastolic PA pressure, mm Hg 9.3 3.1 12.4 5.5 0.001
RV/aortic pressure 0.6 0.2 0.4 0.1 0.001
RV-PA pressure gradient, mm Hg 26.8 18.4 11.7 8.0 0.001
Values are mean  SD.
PA  pulmonary artery; RV  right ventricular.patient during the procedure, but the patient was cardio-verted to sinus rhythm on both occasions with a single
asynchronous shock. Mean post-procedure hospital stay was
2.1  2.0 days.
During 6-month follow-up, 1 patient required a repeat
THV implantation. At discharge, this patient was noted to
have moderate residual estimated gradient across the stented
valve with estimated peak gradient across the right ventric-
ular outflow tract of 69 mm Hg and mild pulmonary
regurgitation as assessed by TTE. It was not clear whether
optimal functionality of the THV was impeded by acute
renarrowing of the valved conduit, and therefore the patient
was brought back to the catheter laboratory for further
high-pressure ballooning of the conduit. A decision was
made at this time to implant a second 23-mm Edwards
SAPIEN THV to ensure that dysfunction of the valve
system was not contributing to these findings. The proce-
dure was uncomplicated, with peak residual gradient of 25
mm Hg measured at the end of the procedure by direct
pullback. However, the gradient at discharge from the
hospital as measured by TTE was found to be 69 mm Hg
with 2 regurgitation. On the 30-day follow-up TTE, the
peak gradient had increased to 89 mm Hg with 3
ulmonary regurgitation. There were no further adverse
vents on follow-up reported. No stent fractures were seen
n the chest radiograph or CT scan at 6-month follow-up.
Significant improvements in NYHA functional class (Fig. 3),
echocardiographic right ventricular outflow tract peak
gradient (Fig. 4), and degree of pulmonary regurgitation
(Fig. 5) persisted at 30-day and 6-month follow-up
compared with baseline.
Interpretable nonpaired follow-up MRI data were avail-
able for 13 patients (38%). These demonstrated significant
improvements in right ventricular volumes (from 130.0 
2.9 ml/m2 to 86.9  19.6 ml/m2, p  0.02) and
pulmonary regurgitant fraction (from 28.6  18.0% to
3.5  5.4%, p  0.001) after valve implantation (Table 2).
No significant changes in variables measured at cardiopul-
monary exercise testing were noted; however, the majority
of patients did not reach the anaerobic threshold, and direct
Intraprocedure Adverse EventsTable 4 Intraprocedure Adverse Events
Patient # Adverse Event Outcome
1 THV migration Surgical removal and surgical PVR
2 THV migration Surgical removal and transapical
delivery of 26-mm Edwards
SAPIEN THV
3 THV migration Successful deployment within the
inferior vena cava
4 Stent embolization to right
ventricle
Surgical removal and surgical PVR
5 Pulmonary hemorrhage Spontaneous resolution without
need for blood transfusion
6 Pulmonary hemorrhage Spontaneous resolution without




current cardioversionPVR  pulmonary valve replacement; THV  transcatheter heart valve.
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November 15, 2011:2248–56 Transcatheter Pulmonary Valve Replacementcomparisons of oxygen consumption in this setting are
difficult to interpret. Subanalysis of circularity index of the
valve (defined as ratio of maximal and minimal valve
diameters measured in orthogonal planes) in 15 patients as
assessed by CT at 6 months demonstrated good mainte-
nance of valve symmetry with a mean circularity index of
0.89  0.15.
Discussion
This study demonstrates excellent short-term functionality
and durability of the Edwards SAPIEN THV when de-
ployed in patients with dysfunctional RV-PA conduits
(regurgitation with or without stenosis). The procedure was
highly effective at reducing immediate pressure gradients
across the conduit with continued effectiveness noted at
6-month follow-up. This is particularly pertinent in light of
recent data suggesting that conduit stenosis relief is associ-
ated with improved exercise capacity in the setting of
pulmonary valve replacement, whereas relief of pulmonary
regurgitation is not (12). The peak gradient across the
conduit was reduced from 41.9  26.2 mm Hg pre-
procedure to 23.0  13.8 mm Hg at discharge. There was
a further reduction at 6 months with a mean peak SAPIEN
THV gradient of 19.1  13.3 (Fig. 4A). Considering the
reported impact of flow turbulence on valve calcification in
the setting of native semilunar valves (13), this continued
early reduction in valve gradient is relevant. Another factor
known to affect recurrent transvalvular pressure gradients is
Figure 3 New York Heart Association Functional Classification
This demonstrates the majority of patients with NYHA (New York Heart Associationstent fracture. This complication was not encountered inour cohort; however, fractures have been reported with the
only other currently available transcatheter pulmonary valve
(Medtronic Melody valve). In recent reports describing
experience with the Melody valve, stent fractures were seen
in as many as 30% of patients (2,3) with 8% detected within
6 months of valve implantation (3). Pre-stenting of the
conduit may reduce the risk of Melody valve stent fractures;
however, this is still considerable at 1 year, with rates as high
as 18% reported (14). All patients undergoing THV im-
plantation in this study had pre-stenting performed. It is
likely that this contributed to early stent valve durability;
however, the absence of pre-stenting support has not
affected valve integrity in more than 300 patients with
SAPIEN valve implants in the aortic position, with no
fractures reported at 1-year follow-up (6,15).
The durability of the Edwards SAPIEN valve was also
evident when assessing valvular competence. No cases of
acute valve failure were seen, and at 6 months, the Edwards
valve maintained effective pulmonary competence (2) in
97% of patients. This is in contrast to previously reported
surgical series of pulmonary valve replacement. Acute pul-
monary conduit failure requiring reoperation after surgical
replacement was reported in 2 of 71 patients by Oosterhof
et al. (16). Frigola et al. (17) demonstrated a pulmonary
regurgitant fraction of 30% or greater in 7% of patients after
surgical valve replacement as assessed by MRI at 1-year
follow-up. One patient in our study was noted to have
progressive pulmonary regurgitation and valve gradient at
aseline and Follow-Up
tional class I at 6-month follow-up.at B
) funcdischarge. This was thought to be secondary to the asym-
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which may have had an impact on valve function. The
patient underwent further valve balloon dilation and valve
implantation 2 days after the original procedure; however, the
residual pressure gradient and pulmonary regurgitation per-
sisted, suggesting that dysfunction of the original valve was not
contributory. This prompted a subanalysis of valve symmetry in
15 patients at 6 months as assessed by CT scan to determine
Figure 4 Box Plots Demonstrating Changes in Echocardiograph
(A) Estimated peak pressure gradient across the pulmonary outflow assessed by
(B) Reduction in mean pressure gradient across the pulmonary outflow assessedthe effect of potential asymmetry on valve function. Thisdemonstrated excellent maintenance of valve circularity with a
mean circularity index of 0.89  0.15. In 2 patients with
indices0.8, pulmonary incompetence was described as trivial
or none. It is noteworthy that the patient who underwent a
second percutaneous valve implantation required surgical re-
moval of the 2 valves and placement of a 25-mm Freestyle
valve (Medtronic Inc.) 8 months later (outside the 6-month
follow-up window of this study). However, 5 months after this
y Derived Gradients at Baseline and Follow-Up
oracic echocardiography (TTE) at baseline and follow-up.
at baseline and follow-up in patients after implantation of a 26-mm valve.icall
transth
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November 15, 2011:2248–56 Transcatheter Pulmonary Valve Replacementstruction with a peak gradient of 75 mm Hg, which may
eflect a tendency toward abnormally accelerated bioprosthetic
alve degeneration in this particular substrate.
Seven patients experienced procedure-related adverse
vents. Three of these required operative interventions for
ither stent or THV migration, and this is similar to
perative interventions after initial experience with the
elody valve (2). Two of these patients underwent tradi-
ional surgical pulmonary valve replacement without com-
lication. In another in whom the THV had migrated
roximally after deployment, it was possible to remove the
igrated valve and place another valve as discussed previ-
usly (11). One further patient had the SAPIEN valve
eployed in the inferior vena cava due to proximal stent
igration on balloon inflation with further successful trans-
atheter SAPIEN valve implantation during the same
rocedure. The potential causes for valve migration include
uboptimal valve positioning within the pre-stented RV-PA
onduit. This underscores the importance of optimal valve
eployment, in the middle of the deployed stent. Pre-
tenting will certainly abolish any residual conduit valve
ompetence leading to significant alternating flows also
otentiating valve instability during inflation. As the
APIEN valve is mounted on a single balloon, operator
xperience is important in countering these factors to
aximize optimal valve positioning. Other technical aspects
elating to implantation of the SAPIEN valve in the
ulmonary position have been previously reported (7). It is
orth pointing out that valve size did not affect the safety or
Figure 5 Severity of Pulmonary Regurgitation Assessed by TTE
Two patients’ initial transthoracic echocardiography (TTE) assessment of pulmonafficacy of the procedure. Eight patients had successfulimplantation of a 26-mm valve with sustained significant
reduction in RV-PA conduit valve pressure gradients at 6
months (Fig. 4B). In 2 of these patients, the minimum
conduit diameter was 23 mm, which exceeds the recom-
mended diameter for implantation of the Melody valve. The
26-mm valve thus extends the number of patients eligible
for transcatheter valve implantation without affecting dura-
bility at 6 months. No further post-procedure complications
including conduit aneurysm formation or pulmonary embo-
lism were seen on 6-month follow-up CT scan.
A significant improvement in functional class was noted
at 6 months post-procedure compared with baseline (Fig. 3).
Previous studies have sought to objectively define improve-
ment in exercise tolerance (due to a predominant lack of
symptoms in many patients with pulmonary regurgitation)
with cardiopulmonary exercise testing; however, in most
studies to date, little or no difference has been shown
(3,4,17). The majority of patients in this study failed to
reach the anaerobic threshold, and therefore changes in
peak oxygen consumption were difficult to interpret because
many confounding variables affecting these values, particu-
larly physical deconditioning, may be present. This repre-
sents one of the limitations of this study; however, similar
difficulties have been experienced in previous studies assess-
ing tPVR, and the benefits of cardiopulmonary exercise
testing with continued difficulties in data interpretation in
this setting must be questioned. Difficulties also arose when
assessing MRI data with 50% of the initial cohort with
interpretable ventricular volumes and regurgitant fractions,
aseline and Follow-Up
rgitation (0 and 1 above) were performed before pre-stenting.at B
ry reguand this represents another limitation with our data. Pre-
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stents may lead to radiofrequency shielding within the
stented area (18), exacerbating problems with direct assess-
ment of pulmonary regurgitant fraction. This may not have
been such an issue with the Melody valve due to the initial
absence of pre-stenting, and less artifact maybe seen with
platinum stents (18), although valid MRI data even in the
absence of presenting with this valve has been reported to be
as low as 48% (2). Indeed, MRI in this setting was initially
described in patients undergoing surgical pulmonary valve
replacement to evaluate right ventricular volumes above
which the right ventricle may not normalize (16,17,19).
Patients undergoing tPVR are more likely to have mixed
stenosis/regurgitation, and indexed right ventricular vol-
umes at the time of intervention have been significantly less
than those reported in the cited surgical series, with pre-
dominant regurgitant lesions (3,20). It remains to be seen
whether early surveillance to confirm pulmonary valve com-
petence and reduction in right ventricular volumes with
MRI will continue to be necessary in the setting of tPVR.
Conclusions
The 6-month follow-up data have demonstrated the Ed-
wards SAPIEN THV to be safe and effective when used in
patients with significant pulmonary regurgitation with or
without stenosis in RV-PA conduits between 16 and 24 mm
in size. Significant improvements in pressure gradients,
pulmonary regurgitation, and symptoms were noted. Ex-
tended application of this valve in the pulmonary position
with ongoing follow-up is required to determine whether
these results are sustainable over a longer time period and
broader population.
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